Enroll in a Study
End-Stage Renal Disease & Dialysis
Current Studies
R1 Therapeutics_Alebund 306
Study Details
Approximately 18–20 weeks
Patient Information
Do you receive hemodialysis and struggle with high phosphorus levels?
The AP306-HP-202 Study is evaluating AP306, a potential new treatment designed to reduce phosphate absorption and improve phosphorus control in people receiving maintenance hemodialysis.
Throughout the study, you will receive high-quality medical care from our dedicated research team. This includes regular health assessments, monitoring, and support, ensuring that your well-being is closely observed and managed.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
Physician Information
Target population: Adults 18 years and older with hyperphosphatemia receiving maintenance hemodialysis for End-Stage Kidney Disease (ESKD), on a stable dialysis regimen at least three times weekly.
The problem: Hyperphosphatemia (high blood phosphate levels) is a common complication in patients with advanced chronic kidney disease and those receiving dialysis. Elevated phosphate levels are associated with increased risks of:
- Cardiovascular disease
- Bone fractures
- Hospitalization
- Mortality
Why the problem exists: Damaged kidneys cannot effectively remove excess phosphorus from the body
New approach to solve the problem: AP306 is a novel oral medication designed to block multiple intestinal phosphate transporters (NaPi-IIb, PiT-1, and PiT-2), reducing phosphate absorption from the gastrointestinal tract before it enters the bloodstream. This mechanism differs from traditional phosphate binders and may provide more effective phosphate control.
Study: Researchers are studying AP306, an investigational oral medication designed to reduce the amount of phosphorus absorbed from food. The goal is to determine whether AP306 can help dialysis patients better control high phosphate levels while remaining safe and well tolerated.
Study duration: Approximately 18–20 weeks total
New intervention: AP306 (formerly AP-306 / EOS789)
Study purpose: To determine:
- Whether AP306 safely lowers serum phosphate levels
- The optimal dose regimen (BID vs TID)
- The proportion of participants who achieve target phosphate levels
- Effects on intact parathyroid hormone (iPTH) and fibroblast growth factor 23 (FGF23)
- Overall safety and tolerability in dialysis patients.
Sponsor Name: R1 Therapeutics
PI(s): Dr. Adam Horeish
Sign Up Today
If you have questions about Balboa Research,
please complete the contact form or call
George Nilsson, Clinical Research Director.
George Nilsson
Clinical Research Director
(858) 810-8072